



Article

Expression Profiling along the Murine Intestine: Different Mucosal Protection Systems and Alterations in *Tff1*-Deficient Animals

Franz Salm¹, Eva B. Znalesniak¹, Aikaterini Laskou¹, Sönke Harder² , Hartmut Schlüter² and Werner Hoffmann^{1,*}

¹ Institute of Molecular Biology and Medicinal Chemistry, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, 39120 Magdeburg, Germany

² Section Mass Spectrometry and Proteomics, Diagnostic Center, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany

* Correspondence: werner.hoffmann@med.ovgu.de

Abstract: *Tff1* is a typical gastric peptide secreted together with the mucin, *Muc5ac*. *Tff1*-deficient (*Tff1*^{KO}) mice are well known for their prominent gastric phenotype and represent a recognized model for antral tumorigenesis. Notably, intestinal abnormalities have also been reported in the past in these animals. Here, we have compared the expression of selected genes in *Tff1*^{KO} mice and their corresponding wild-type littermates (RT-PCR analyses), focusing on different mucosal protection systems along the murine intestine. As hallmarks, genes were identified with maximum expression in the proximal colon and/or the duodenum: *Agr2*, *Muc6/A4gnt/Tff2*, *Tff1*, *Fut2*, *Gkn2*, *Gkn3*, *Duox2/Lpo*, *Nox1*. This is indicative of different protection systems such as *Tff2/Muc6*, *Tff1-Fcgbp*, gastrokines, fucosylation, and reactive oxygen species (ROS) in the proximal colon and/or duodenum. Few significant transcriptional changes were observed in the intestine of *Tff1*^{KO} mice when compared with wild-type littermates, *Clca1 (Gob5)*, *Gkn1*, *Gkn2*, *Nox1*, *Tff2*. We also analyzed the expression of *Tff1*, *Tff2*, and *Tff3* in the pancreas, liver, and lung of *Tff1*^{KO} and wild-type animals, indicating a cross-regulation of *Tff* gene expression. Furthermore, on the protein level, heteromeric *Tff1-Fcgbp* and various monomeric *Tff1* forms were identified in the duodenum and a high-molecular-mass *Tff2/Muc6* complex was identified in the proximal colon (FPLC, proteomics).

Keywords: trefoil factor; TFF; *Fcgbp*; colon cancer; mucin; *Muc6*; goblet cell; Brunner gland; innate immunity; reactive oxygen species



Citation: Salm, F.; Znalesniak, E.B.; Laskou, A.; Harder, S.; Schlüter, H.; Hoffmann, W. Expression Profiling along the Murine Intestine: Different Mucosal Protection Systems and Alterations in *Tff1*-Deficient Animals. *Int. J. Mol. Sci.* **2023**, *24*, 12684. <https://doi.org/10.3390/ijms241612684>

Academic Editor: Alfred King-Yin Lam

Received: 10 July 2023

Revised: 3 August 2023

Accepted: 4 August 2023

Published: 11 August 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The intestinal tract consists of two major segments, i.e., the small intestine (duodenum, jejunum, and ileum) and the large intestine (caecum, colon, and rectum), which differ in their morphology [1]. The lumen is lined by a delicate mucous epithelium, which is protected by different mechanisms, one being the continuous self-renewal from stem and precursor cells [2]. The various parts of the intestine have different physiological functions concerning the digestion of food, the absorption of nutrients, and the excretion of fecal pellets. The number of bacteria drastically increases towards the colon [3,4]. For example, the distal ileum contains about 10⁸ bacteria per milliliter of luminal content and the colon contains about 10¹¹ [5]. The mucosa-associated microbiota differ along the intestinal tract, including at least three different bacterial ecosystems with significant differences between the distal ileum and caecum, and also between the ascending colon and the transverse colon [6]. The large number of bacteria in the colon is likely the reason why it is protected by a two-layered mucus barrier, the inner layer not being penetrable for bacteria [5,7]. In contrast, the small intestine is covered by a single mucus layer [5]. The predominant mucin in the murine intestine is *Muc2*, which is a typical secretory

product of different types of goblet cells [8]. Mucin glycosylation is an important element in the regulation of the intestinal microbiota. In mice, the small intestine is dominated by sialylated glycans, whereas in the colon, fucosylation dominates [9]. Other typical secretory products of intestinal goblet cells are the trefoil factor family (TFF) peptide, Tff3; IgG Fc binding protein (Fcgbp); and the calcium-activated chloride channel regulator 1 and metalloprotease Clca1 (previously: Gob5) [10–13]. Remarkably, at least in humans, TFF3 and FCGBP form disulfide-linked heteromers [10] and there are multiple indications that FCGBP and TFF3-FCGBP play a key role in the innate immune defense of mucous epithelia [12,14,15]. Furthermore, the protein disulfide isomerase, Agr2, is essential for the production of mucus [16]. It is located in the endoplasmic reticulum and also occurs in a secreted form [17].

Another source of intestinal mucous protection are the Brunner glands, which are localized in the proximal duodenum only, and are usually not found beyond the entrance of the pancreatic duct [18]. As a hallmark, they secrete the mucin Muc6, which contains the unusual terminal carbohydrate moiety $\text{GlcNAc}\alpha 1 \rightarrow 4\text{Gal}\beta 1 \rightarrow \text{R}$ (review: [19]). The key enzyme for the synthesis of the αGlcNAc residue is $\alpha 1,4\text{-N-acetylglucosaminyltransferase}$ encoded by the *A4gnt* gene [19]. The αGlcNAc residue is recognized by the lectin GSA-II from *Griffonia simplicifolia* [20]. Of particular note, the TFF peptide Tff2 is a lectin, which binds to $\text{GlcNAc}\alpha 1 \rightarrow 4\text{Gal}\beta 1 \rightarrow \text{R}$ and physically stabilizes the mucus barrier by crosslinking Muc6 (review: [21]). The combined expression of the Muc6/A4gnt/Tff2 system is not restricted to Brunner glands, but is also observed in gastric mucous neck and antral gland cells (MNCs, AGCs), and is conserved from frog to human [19–22]. This explains why Tff2 and Muc6 are co-localized in the gastric mucus [23].

Protection of the intestinal mucosa is also greatly facilitated by extracellular reactive oxygen species (ROS), in particular hydrogen peroxide (H_2O_2) and the superoxide anion radical, $\text{O}_2^{\bullet -}$, which are part of the innate immune defense directly attacking microorganisms [24,25]. Furthermore, ROS also trigger signaling cascades important for mucosal healing and regeneration [25]. Generation of these “primary ROS” occurs via the NOX/DUOX family of transmembrane NADPH oxidases in epithelial cells [25–28]. In the intestine, Nox1 generates superoxide, whereas Duox2 is responsible for the production of extracellular H_2O_2 [25]. The latter is then used by secretory lactoperoxidase (Lpo), primarily to oxidize thiocyanate (SCN^-) into the potent microbicidal component hypothiocyanite (OSCN^-), which is effective against a wide range of microorganisms (DUOX/ H_2O_2 /LPO/ SCN^- system) [28]. Excess of extracellular superoxide is destroyed by the extracellular superoxide dismutase Sod3, generating H_2O_2 [29]. Further protection systems include gastrokines (Gkn1-3) [30], antimicrobial peptides from Paneth cells of the small intestine [31], and the intestinal immune system [32].

TFF peptides are evolutionary old lectins with important roles in mucosal protection and repair (reviews: [33–35]). They even occur in the skin and gastrointestinal (GI) tract of the frog *Xenopus laevis* [36,37]. The most prominent phenotype in mice has been observed after inactivation of the *Tff1* gene (*Tff1*^{KO} mice) [38]. These animals obligatorily develop antral/pyloric adenoma and carcinomas have been detected in about 30% [38]. Thus, Tff1 is considered as an antral tumor suppressor (reviews: [39,40]). Expression profiling of the stomach revealed significant differences in *Tff1*^{KO} mice when compared with the corresponding wild-type animals [41]. Remarkably, also intestinal abnormalities have been reported for *Tff1*^{KO} mice, i.e., enlarged villi and abnormal infiltration of lymphoid cells [38,39]. Thus, we expanded our previous studies [41] to the intestine. Notably, *Tff1* expression has not been detected in the adult murine intestine in the past [42]. However, delivery of Tff1 via engineered *Lactococcus lactis* or via the transgenic expression of TFF1 was found to increase resistance to intestinal damage in mice [43,44]. Here, we present the systematic expression profiling of six different regions of the murine intestine and compare *Tff1*^{KO} mice with the corresponding wild-type littermates at the age of six weeks. The focus is on genes involved in various mucosal protection systems. Furthermore, we present protein data concerning Tff1 in the duodenum and Tff2 in the caecum/colon.

2. Results

2.1. Expression Profiling of the Murine Intestine (RT-PCR Analysis)

Relative gene expression levels were monitored in six different regions of the intestinal tract of *Tff1*^{KO} mice as well as their corresponding wild-type littermates (Figure 1).




Figure 1. Semi-quantitative RT-PCR analyses. *A4gnt*, *Agr2*, *Cdx1*, *Cdx2*, *Clca1*, *Duox2*, *Fcgbp*, *Fut2*, *Gast*, *Gkn1*, *Gkn2*, *Gkn3*, *Mki67*, *Lgr5*, *Lpo*, *Muc2*, *Muc6*, *Nox1*, *Pdia3*, *Pdia6*, *Pdx1*, *Qsox1*, *Sod1*, *Sod2*, *Sod3*, *Spdef*, *Tff1*, *Tff2*, *Tff3*, and *Zg16* expression in different parts of the murine intestine, i.e., proximal, medial, and distal parts of the duodenum (pD, mD, dD), middle section of the jejunum (J), distal ileum (I), and proximal/ascending colon (aC). Extracts of 10 female wild-type (WT, black bars) and 10 female *Tff1*^{KO} mice (white bars) were investigated. The number of amplification cycles is given after each gene. The relative gene expression levels were normalized against β -actin (*Actb*, 23x or 24x). Significances are indicated by asterisks (*, $p \leq 0.05$; **, $p \leq 0.01$; ***, $p \leq 0.001$).

The expression profiling (Figure 1) included transcripts encoding of TFF peptides (*Tff1*, *Tff2*, *Tff3*); gastrokines (*Gkn1*, *Gkn2*, *Gkn3*); goblet cell products (*Fcgbp*, *Clca1*, *Muc2*, *Zg16*); disulfide isomerases (*Agr2*, *Pdia3*, *Pdia6*, *Qsox1*); the mucin *Muc6*; glycosylation enzymes (*A4gnt*, *Fut2*); enzymes involved in the metabolism of ROS (*Nox1*, *Duox2*, *Lpo*, *Sod1*, *Sod2*, *Sod3*); transcription factors (*Cdx1*, *Cdx2*, *Pdx1*, *Spdef*); the hormone gastrin (*Gast*); the stem cell marker *Lgr5*, and the proliferation marker *Ki67* (*Mki67*).

Generally, four kinds of gene expression profiles were observed within the intestine: (i) genes expressed in about equal amounts along the intestine (*Cdx1*, *Cdx2*, *Fcgbp*, *Clca1* (previously: *Gob5*), *Mki67*, *Lgr5*, *Muc2*, *Pdia3*, *Pdia6*, *Sod1*, *Sod2*, *Sod3*, *Tff3*, *Zg16*); (ii) genes with a maximum expression in the duodenum (*Gast*, *Gkn1*, *Gkn2*, *Gkn3*, *Pdx1*); (iii) genes, whose expression peaked in both the duodenum and the colon (*A4gnt*, *Agr2*, *Fut2*, *Muc6*, *Spdef*, *Tff1*, *Tff2*); (iv) genes with maximum expression in the colon (*Duox2*, *Lpo*, *Nox1*).

The most significant differences between wild-type and *Tff1*^{KO} mice were observed for the following genes (other than *Tff1*): *Gkn1*, *Gkn2*, *Clca1* (previously: *Gob5*), *Lgr5*, *Nox1*, *Spdef*, and *Tff2*. Here, differences were considered as being relevant when significance (*) was observed in at least two different regions or high significance (**) was observed in at least one region.

2.2. Expression Profiling of Tffs in the Murine Pancreas, Liver, and Lung (RT-PCR Analysis)

In the past, the expression of *Tff* genes was repeatedly documented to be changed in *Tff1*^{KO} mice as shown for the stomach [38,41] and the intestine (Figure 1). In order to complete these studies concerning other organs known for their *Tff* expression, we also investigated the pancreas, liver, and lung (Figure 2).




Figure 2. Semi-quantitative RT-PCR analyses (murine pancreas, liver, and lung). *Tff1*, *Tff2*, and *Tff3* expression was monitored in extracts of 10 female wild-type (WT, black bars) and 10 female *Tff1*^{KO} mice (white bars). The number of amplification cycles is given after each gene. The relative gene expression levels were normalized against β -actin (*Actb*; pancreas 27x, liver 24x, lung 21x). Significances are indicated by asterisks (***, $p \leq 0.001$).

In the pancreas, both *Tff2* and *Tff3* expression were significantly reduced in *Tff1*^{KO} mice. In contrast, in the liver of *Tff1*^{KO} mice, only *Tff3* expression was significantly decreased, whereas in the lung of *Tff1*^{KO} mice, only *Tff2* expression was significantly down-regulated.

2.3. Protein Analysis of the Murine Duodenum

As *Tff1* transcripts were not detected in the small or large intestine in the past [42], we checked the positive RT-PCR results concerning *Tff1* (Figure 1) on the protein level. Here, a duodenal extract was separated via SEC, as reported previously [22], and analyzed for its Tff1 content (Figure 3). As a positive control, the Tff3 content was also determined.




Figure 3. Analysis of a murine duodenal extract (complete duodena from four animals). The elution profile after SEC on a Superdex 75 HL column as well as the distribution of Tff2 have been reported previously [22]. (A) Distribution of the relative Tff1 (black) and Tff3 contents (green) as determined via Western blot analysis under reducing conditions and semi-quantitative analysis of monomeric band intensities. For Tff1, a regular band (black drawn line) and a somewhat shortened band (black dashed line) were analyzed separately. For comparison, the fractions were analyzed for their mucin content using the PAS reaction (pink); (B) 15% SDS-PAGE under reducing (R) and non-reducing (NR) conditions (post-in-gel reduction), respectively, and Western blot analysis of the high-molecular-mass fraction B8 and the low-molecular-mass fractions D3 and D5 concerning Tff1. As a control, fraction D1 from a murine stomach extract (St; [22]) was analyzed. (C) Analysis of the high-molecular-mass fractions B8–B10 concerning Tff3; (D) 1% AgGE and Western blot analysis of the high-molecular-mass fractions B8 and B9 concerning Tff3, Fcgbp, and Tff1, respectively (D, duodenal extract; Cae+C, extract from caecum plus total colon). Relative standard: DNA ladder (base pairs).

Two Tff1 forms were detectable. In the high-molecular-mass region, it was mainly a slightly shortened Tff1 band that was found under reducing conditions (Figure 3A,B), which is barely detectable under non-reducing conditions, indicative of a disulfide-linked heterodimer (Figure 3B). In contrast, in the low-molecular-mass region, a regular and a shortened band were present (Figure 3A,B), which were both detectable also under non-reducing conditions, indicative of monomeric Tff1 (Figure 3B).

Tff3 appeared mainly in a high-molecular-mass form, and only minute amounts of a low-molecular-mass form were present (Figure 3A). From the high-molecular-mass form, Tff3 could be released after reduction (Figure 3C), and this band was partially shifted after non-reducing SDS-PAGE (arrow in Figure 3C).

As human TFF3 is known to form disulfide-linked TFF3-FCGBP heterodimers [10,15,45], we checked if Tff3-Fcgbp was detectable in the high-molecular-mass region (Figure 3D). Clearly, Tff3-Fcgbp was present in the duodenum. Furthermore, Tff1-Fcgbp was also detectable (Figure 3D).

In order to verify the different Tff1 immunoreactive bands in the high- and low-molecular-mass regions (Figure 3A,B), the corresponding bands from fractions B8, D1, D3, and D5 (Figure 4A,B) were eluted and Tff1 was identified via bottom-up proteomics (Figure 4C). As a reference for the Tff1 sequence, Tff1 was isolated from the high-molecular-mass region of a murine stomach extract described previously [22] and analyzed in parallel (Figure 4C). For comparison, Tff3 was also identified in band B8 (Figure 4C).




Figure 4. Proteome analysis of the high- and low-molecular-mass forms of Tff1 in a duodenal extract (fractions B8, and D1, D3, and D5 from Figure 3). (A,B) SDS-PAGE under reducing conditions of the high-molecular mass fractions B7–B10 (A) and the low-molecular-mass fractions C12–D7 (B) and Western blot analysis concerning Tff1. Fractions B8, D1, D3, and D5 were then separated via preparative reducing of SDS-PAGE, and after Coomassie staining, bands termed B8, D1, D3a, D3b, and D5 were excised (marked in red). (C) Results of the proteome analyses after tryptic in-gel digestion of bands B8, D1, D3a, D3b, and D5. Identified regions in Tff1 are shown in red. In B8, Tff3 was also identified. The results of the Tff1 reference (from a stomach extract) are also shown. The longest N-terminal sequences identified are shown. (D) Identification of heterogeneous Tff1 N-terminal sequences in bands D3b and the stomach reference (q indicates a pyro-Glu residue). The predominant sequences are underlined.

2.4. Protein Analysis of the Murine Large Intestine

In contrast to the positive RT-PCR analysis presented in Figure 1, *Tff2* mRNA was not observed in the murine large intestine in the past [42]. Thus, we checked *Tff2* synthesis in the large intestine on protein level (Figure 5). As a positive control, the *Tff3* content was analyzed.

Tff2 was exclusively detectable in a high-molecular-mass form (Figure 5A), which can be released under reducing as well as non-reducing conditions (Figure 5B). This high-molecular-mass region also contains *Muc6*, as detected via staining with the lectin GSA-II (Figure 5C). Furthermore, the presence of *Tff2* was verified via bottom-up proteomics in the high-molecular-mass fraction B8 after reducing SDS-PAGE (Figure 5D,E).

Tff3 exists in a high-molecular-mass form (Figure 5A). After AgGE, this form was mainly identified as *Tff3-Fcgbp* (Figure 3D). However, there was also a second *Tff3*-positive band with a somewhat lower molecular mass, which was not positive with the anti-Fcgbp antiserum used (Figure 3D).




Figure 5. Analysis of a murine caecum plus total colon extract (single individual). (A) Elution profile after SEC on a Superdex 75 HL column as determined via absorbance at 280 nm (PAS-positive mucin fractions: pink). Underneath: distribution of the relative Tff2 (red) and Tff3 contents (green) as determined via Western blot analysis under reducing conditions and semi-quantitative analysis of the monomeric band intensities; (B) 15% SDS-PAGE under reducing (R) and non-reducing (NR) conditions (post-in-gel reduction), respectively, and Western blot analysis of the high-molecular-mass fractions B8–B10 concerning Tff2; (C) 1% AgGE and Western blot analysis of the fractions B6–C2 concerning Muc6 (lectin GSA-II). Relative standard: DNA ladder (base pairs). (D) SDS-PAGE under reducing conditions of fraction B8. Shown is a Western blot analysis concerning Tff2 and in parallel, Coomassie staining. Bands 1 and 2 were excised for proteome analysis. (E) Results of the proteome analysis after tryptic in-gel digestion of bands 1 and 2. Identified regions in Tff2 are shown in red.

3. Discussion

3.1. Expression Profiling along the Murine Intestinal Tract: Indications for Different Mucosal Protection Systems

As controls, expression profiles of the genes encoding the transcription factors *Cdx1*, *Cdx2*, and *Pdx1* were monitored (Figure 1). Expression of the intestine-specific genes *Cdx1* and *Cdx2* is rather uniform with a slight upregulation in the colon. In contrast, the transcription factor *Pdx1* is known to regulate, in particular, endocrine differentiation in the gastric antrum, pancreas, and duodenum [46], which is in agreement with its expression in all three regions of the duodenum. Furthermore, expression of the hormone gastrin, particularly in the proximal duodenum, is as expected.

Generally, the expression profiling of genes encoding proteins known to play a role in the mucosal innate immune defense, such as Tff peptides, gastrokines, mucins, Fcgbp, and enzymes involved in the metabolism of ROS, point to different mucosal protection systems along the murine intestinal tract. On the one hand, secretory products of goblet

cells protect the entire intestine (basic protection system). On the other hand, there are additional, specific protection systems, particularly in the proximal duodenum as well as the proximal colon.

3.1.1. Basic Protection of the Entire Intestinal Tract by Goblet Cell Products (Muc2, Tff3-Fcgbp)

Genes encoding typical secretory proteins of goblet cells, i.e., *Clca1* (previously: *Gob5*), *Fcgbp*, *Muc2*, *Tff3*, and *Zg16*, show a rather uniform expression profile along the murine intestine (Figure 1). This result is not surprising as it reflects the common view that the complete intestine is protected by a mucus barrier produced by goblet cells, Muc2 being the predominant mucin. Another known component is the Tff3-Fcgbp heteromer, which has been demonstrated, e.g., in duodenal and colonic extracts (Figure 3D), and presumably plays a role for the mucosal innate immune defense [14,47].

For comparison, Tff3 was identified via proteomics in the high-molecular-mass Tff3-Fcgbp complex of the duodenum after reduction (Figure 4C). Because of its abundance, the complete Tff3 sequence could be determined, indicating for the first time, unambiguously cleavage of the signal peptidase after Ala-23 of the precursor.

Notably, the expression of *Spdef* increases towards the colon with an additional peak in the proximal duodenum (Figure 1). This might be due to the increasing percentage of goblet cells relative to the total number of epithelial cells from the duodenum to the colon, as the transcription factor *Spdef* regulates terminal differentiation of goblet cells [48]. The peak in the proximal duodenum is caused by additional *Spdef* expression in Brunner glands [48].

3.1.2. Specific Protection of the Proximal Duodenum and the Colon by the Tff2/Muc6 Complex

In the intestine, *Tff2*, *Muc6*, and *A4gnt* are predominantly expressed in the proximal duodenum (Figure 1). This is in agreement with their known synthesis in Brunner glands [19,22,42], which are located in the proximal duodenum only and are usually not found beyond the entrance of the pancreatic duct [18,49]. Thus, co-expression of *Tff2*, *Muc6*, and *A4gnt* in Brunner glands allows formation of a lectin-mediated, high-molecular mass Tff2/Muc6 complex, as already demonstrated on the protein level in murine duodenal extracts [22]. When compared with the murine stomach [41], the expression of *Tff2*, *Muc6*, and *A4gnt* in the intestine is much lower.

Of particular note, the expression of *Tff2*, *Muc6*, and *A4gnt* was also detectable in the proximal colon (Figure 1). In the past, there were contradictory reports concerning *Tff2* transcripts in the murine colon. They were either not detected [42] or described as being expressed in colonic epithelial cells [50], which might reflect differences between different mouse strains. However, immunohistochemistry of the proximal colon of rats localized Tff2 strongly in the lower parts of the crypts [51]. Thus, we tested an extract from caecum plus total colon for the presence of Tff2 (Figure 5). We could clearly identify a high-molecular-mass Tff2/Muc6 complex (Figure 5A), which was positive for GSA-II (Figure 5C), indicative of terminal GlcNAc residues in Muc6 due to A4gnt activity (Figure 5C). Tff2 was also identified via proteomics (Figure 5E). Notably, we could identify Tff2 not only in band 1, which is equivalent to the band strongly immunoreactive for Tff2 (Figure 5D), but Tff2 was also clearly identified in a band below with only weak immunoreactivity (designated as band 2: Figure 5D). This band can also be seen in Figure 5B and probably represents a shortened variant, maybe missing a few amino acid residues at the N- or C-terminal. However, the question of the cellular origin of this Tff2/Muc6 complex arises, as goblet cells are not known for the synthesis of Tff2.

In the past, the unusual GlcNAc-residue typical of Muc6 was recognized in gastric MNCs and AGCs as well as in Brunner glands, but also in the deep crypt cells of the rat colon [52,53]. These cells were first described by Altmann as “deep crypt secretory (DCS)” cells, particularly in the rat ascending and transverse colon, which originate from precursor cells and typically secrete mucus [54]. Later on, these cells were recognized again, due

to their expression of *Agr2* (previously termed *Gob4*) and typical staining with Alcian blue [16,55]. Notably, these Alcian blue positive DCS cells can be clearly distinguished from goblet cells, the latter being characterized by the synthesis of *Tff3* [16]. Alcian blue is known to stain acidic mucins, such as *Muc6* in gastric MNCs and AGCs, which are the characteristic *Agr2*-expressing cells in the murine stomach [56]. This implies that the disulfide isomerase *Agr2*, probably together with the disulfide isomerases *Pdia3* and *Pdia6* [57], plays a major role in the folding of *Muc6*, particularly in gastric MNCs and AGCs, as well as in duodenal Brunner glands and colonic DCS cells. This assumption is supported by the RT-PCR analysis concerning *Agr2*, which peaks in the proximal duodenum and proximal colon (Figure 1). It is also in line with a recent report describing *Agr2* as a marker of colonic DCS cells, whose expansion is regulated by interleukin (IL)-13 originating from type 2 innate lymphoid cells (ILC2) [58]. However, *Agr2* has been reported to occur in all intestinal secretory cell types [16], but reaches its highest level in the proximal colon [17]. Taken together, the synthesis of a *Tff2/Muc6* complex in the DCS cells of the colon is comparable with the situation in the gastric antrum (review: [40]). Of particular note, *Lgr5*⁺ stem cells are located at the base of both the colonic crypts and antral glands [59]. Thus, it is tempting to speculate that the *Tff2/Muc6* complex protects these basal stem cells in the colon from microbial colonization via a highly viscous mucous plug. This is in agreement with the view that DCS cells are important components of the colonic stem cell niche [60]. In contrast, the *Lgr5*⁺ stem cells in the small intestine are protected by secretory products of the neighboring Paneth cells, which are lacking in the colon [59].

3.1.3. Specific Protection of the Duodenum by *Tff1* and Gastrokines

Tff1 and the gastrokine genes *Gkn1*, *Gkn2*, and *Gkn3* are also expressed selectively in the duodenum (Figure 1), but at much lower levels when compared with the stomach [41]. The intestinal expression of *Tff1* was somewhat surprising, as *Tff1* transcripts were neither detected in the small nor the large intestine in the past [42]. As the expression of *Tff1* and gastrokines is not confined to the proximal duodenum, expression in goblet cells might be possible. This view is supported by the observation that *Tff1* exists in a high-molecular-mass form (Figure 3A), which has been identified as *Tff1-Fcgbp* heterodimer (Figure 3D), *Fcgbp* being typically secreted by goblet cells. *Tff1-Fcgbp* has already been described as occurring in the murine as well as the human stomach [41,61]. Thus far, it is not clear why *Tff1-Fcgbp* is mainly present in the duodenum and hardly detectable in the colon (Figure 3D); a possible reason may be different types of goblet cells, which differ in their *Tff1* synthesis.

Proteomics clearly verified the existence of different *Tff1* entities in the duodenum in both the high- and low-molecular-mass range (Figure 4). The high-molecular-mass form mainly exists in a shortened variant (Figure 3A,B and Figure 4A). The low-molecular-mass forms consist of a normal and shortened forms, the latter missing up to seven amino acid residues at least at the N-terminal (bands D3b and D5; Figure 4C,D) when compared with the longest *Tff1* form from the murine stomach as a reference (Figure 4C,D). The heterogeneities at the N-terminal of *Tff1* in the duodenum as well the stomach are remarkable (Figure 4D). In the stomach, the *Tff1* precursor is preferentially cleaved by signal peptidase after Ala-21 or after Ala-23, liberating an unusual N-terminal repetitive sequence starting with a pyro-Glu residue (qAQAQAQAQE... and qAQAQAQE..., respectively, Figure 4D), due to cyclization of an N-terminal Gln residue with the help of glutaminyl cyclase. Currently, it is not clear how the multiple N-terminally-truncated *Tff1* forms in the duodenum are generated (Figure 4D); it is possible that alternative cleavages by signal peptidase occur after various Gln or Ala residues and degradation by aminopeptidases. Notably, two forms were identified also starting with a pyro-Glu residue (qAQAQE..., qAQE..., Figure 4D), indicating cleavage by signal peptidase after Ala-25 and Ala-27, respectively. However, artificial cyclization in the electrospray ionization source cannot be excluded [62].

However, only *Gkn3* expression is significantly higher in the proximal duodenum when compared with the medial and distal parts, which is in line with its documented expression in Brunner glands [63]. As *Gkn3* is characteristically co-expressed with *Tff2* and *Muc6*, not only in Brunner glands but also in gastric MNCs and AGCs [30,63], it might be possible that *Gkn3* supports the protective *Tff2*/*Muc6* complex via a yet unknown mechanism.

3.1.4. Specific Protection of the Proximal Duodenum and the Colon by Epithelial Fucosylation

As a hallmark, *Fut2* is predominantly expressed in the proximal duodenum and the proximal colon (Figure 1). *Fut2* regulates fucosylation of intestinal epithelial cells. On the one hand, epithelial L-fucose is used as a dietary carbohydrate for many bacteria. On the other hand, fucosylation inhibits infection, e.g., from *Salmonella typhimurium* [64]. Of particular note, microbiota induce intestinal epithelial fucosylation by triggering *Fut2* expression [65]. For example, *Bacteroides* have been shown to induce epithelial fucosylation by direct interaction [66–69]. In addition, *Fut2* expression can also be mediated indirectly by interleukin (IL)-22 and lymphotoxin α originating from type 3 innate lymphoid cells (ILC3) [64]. Fucosylation can, e.g., change the signaling of receptors such as TLR4 in the murine colon, which is essential for recovery from mucosal injury in vivo [65]. Furthermore, goblet cells can be distinguished according to their fucosylation pattern, such as intercrypt goblet cells in the colon [70]. In contrast, fucosylation deficiency in mice leads to colitis and adenocarcinoma [71].

Bacteroides have been shown to accumulate in the murine proximal duodenum and also the colon [6]. Starting with the caecum, anaerobic genera appear in the murine lower alimentary tract and there is an increase in the richness (amount of different phylotypes) at this point [6]. These could be the reasons why *Fut2* expression peaks in the proximal duodenum and the proximal colon (Figure 1).

3.1.5. Specific Protection of the Proximal Duodenum and Particularly the Colon by ROS-Generating Enzymes

Extracellular ROS such as the relatively stable (10^{-2} – 10^{-3} s) but weak oxidant H_2O_2 and the instable (10^{-5} s) superoxide are not only used by immune cells but also by mucous epithelia for innate immune defense against microorganisms [24–26]. H_2O_2 is diffusible and preferentially reacts with thiols from cysteine residues, whereas the superoxide anion cannot diffuse through membranes [25]. In the gastrointestinal tract, *Duox2* typically generates extracellular H_2O_2 [25,26,72], which is used by *Lpo* to produce the highly microbicidal hypothiocyanite ($DUOX/H_2O_2/LPO/SCN^-$ system) [28]. Of particular note, *Duox2* and *Lpo* are differentially expressed in the colonic crypts of mice, i.e., *Duox2* expression is located at the upper crypt quintile, whereas *Lpo* transcripts are present in the basal quintile, where stem cells reside [73].

Expression of *Lpo* in the proximal colon (Figure 1) is an indication for a need for specific protection of these locations, controlling non-invasive pathogen colonization of the mucus, and might complement other protection systems such as fucosylation. The appearance of anaerobic genera and the increasing richness, particularly in the colon [6], would easily explain the large amounts of both *Duox2* and *Lpo* needed in order to generate sufficient microbicidal $SCNO^-$.

Furthermore, maximal expression of *Nox1* in the proximal colon (Figure 1) is in line with the drastically increasing number of bacteria in this region and fits with previous reports [25,26]. Notably, *Nox1* is most highly expressed in the lower two thirds of colon crypts [74] and thus might be specifically suited to protect the stem and precursor cells and/or enhance regeneration processes. However, the superoxide generated by *Nox1* can be used to produce $SCNO^-$ only in the presence of *Sod3* and *Lpo*; the latter is also expressed at the basal quintile of the crypts [73].

Sod3 is typically present in luminal fluids as well as in the extracellular matrix and protects against oxidative stress-induced injury. Thus, it is not surprising that the entire intestine is protected by *Sod3* (Figure 1). For comparison, the expression of *Sod1* and *Sod2* were also determined (Figure 1), encoding intracellular superoxide dismutases. These transcripts are far more abundant than that of *Sod3* and were detectable all along the intestine.

3.1.6. Summary of the Different Mucosal Protection Systems along the Murine Intestine

In Figure 6, the different protection systems of the murine intestine are summarized. Clearly, besides a basic protection by goblet cell products along the entire intestinal tract, specific systems have evolved, particularly protecting the proximal duodenum (mainly Brunner glands secretions) and the proximal colon (particularly secretory products of DCS cells). The distal colon was not studied here.




Figure 6. Schematic structure of the murine intestine and its different mucosal protection systems. Shown are stomach (Sto); proximal (pD), medial (mD), and distal parts of the duodenum (dD); jejunum (J); ileum (I); caecum (Cae); ascending/proximal (aC), transverse/medial (tC), and descending/distal colon (dC); rectum (R). The regions investigated in this study via RT-PCR are hatched. The predominant localization of the different intestinal protection systems is indicated.

3.2. Transcriptional Changes in the Intestine of *Tff1*^{KO} Mice

Major changes in *Tff1*^{KO} mice were the significantly increased expression of both *Gkn1* and *Gkn2* in the proximal duodenum (Figure 1). Based on the reported mitogenic activity of a *Gkn1* fragment [75], an expected higher *Gkn1* concentration might be responsible for the thickened villi of the small intestinal mucosa and the presence of inflammatory cells, as described previously [38]. However, macroscopically, we could observe intestinal abnormalities in the proximal duodenum only, i.e., a thickening. The significantly increased expression of *Gkn2* in *Tff1*^{KO} mice might result in secretion of a disulfide-linked *Gkn2* homodimer as being detectable in the gastric antrum of *Tff1*^{KO} mice [41]. The biological function of such a *Gkn2* form, particularly in *Tff1*^{KO} mice, is not known currently.

An additional hallmark is the significant down-regulation of *Tff2* in the proximal colon of *Tff1*^{KO} mice (Figure 1). Theoretically, this could diminish protection of the colonic stem cells by the *Tff2*/Muc6 complex and could lead to increased susceptibility of *Tff1*^{KO} mice to DSS-induced colitis, similarly to what has been reported for *Tff2*^{KO} mice [76]. However, *Tff1*^{KO} mice show the same response in a DSS colitis model as wild-type mice [50]. Thus, one might speculate that the significant up-regulation of *Nox1* expression, particularly in the proximal colon of *Tff1*^{KO} mice (Figure 1), could compensate for the reduced protection from bacterial colonization by the *Tff2*/Muc6 complex.

There is a tendency for up-regulated *Tff3* expression in the duodenum and the proximal colon of *Tff1*^{KO} mice (Figure 1), which is in agreement with a previous report [38]. Furthermore, also gastrin expression shows a tendency for up-regulation in the duode-

num of *Tff1*^{KO} mice (Figure 1). This is in contrast to the antrum, where *Tff1*^{KO} mice show statistically significant down-regulation of *Gast* [41].

Notably, there is a generally up-regulated expression of *Clca1* (previously *Gob5*) and *Lgr5* in the entire intestine of *Tff1*^{KO} mice, which is significant for both genes in the ileum and colon, and additionally for *Lgr5* in the proximal duodenum (Figure 1). The up-regulation of the stem cell marker, *Lgr5*, would be in agreement with reports that TFF1 is able to control cell differentiation by regulating the balance between cell proliferation and death (anti-proliferative and anti-apoptotic effects of TFF1) [38,77–79]. Furthermore, *Agr2* and *Sod1* also show a tendency toward up-regulation in *Tff1*^{KO} mice (Figure 1). Up-regulation of *Agr2* might be a response to latent endoplasmic reticulum (ER) stress [80,81], which could be due to the unfolded protein response (UPR) activated in *Tff1*^{KO} mice [82].

3.3. *Tff* Expression Is Cross-Regulated in the Pancreas, Liver, and Lung of *Tff1*^{KO} Mice

In the past, coordinate regulation of *Tff* genes was observed (review [83]), which is due to the clustered organization of the three *Tff* genes in a head-to-tail orientation within a 40 kb region on chromosome 17q [84]. For example, *Tff2* expression is significantly down-regulated in the stomach of *Tff1*^{KO} mice, particularly in the corpus [38,41,85]. Generally, the linear organization of the *Tff* genes reflects their spatial distribution along the GI tract, strongly suggesting the existence of a locus control region [84]. This region may be affected in the *Tff1*^{KO} mice, resulting in down-regulation of *Tff2* and *Tff3*, particularly in organs of the GI tract. However, epigenetic mechanisms play a major role in the regulation of *Tff* expression [84].

Here, we show that *Tff2* is also significantly down-regulated in the pancreas and the lung of *Tff1*^{KO} animals (Figure 2). In both of these organs, *Tff2* is the predominant TFF peptide. The down-regulation of pancreatic *Tff2* expression is in agreement with a previous report [38]. Loss of pancreatic *Tff2* has been shown to promote formation of intraductal papillary mucinous neoplasms in mice [86]. Thus, it might be possible that *Tff1*^{KO} mice exhibit a similar phenotype due to a secondary effect. Furthermore, as *Tff2*^{KO} mice were reported to have compromised lung structure and function [87], it would also be interesting to investigate the lung of *Tff1*^{KO} animals in detail.

In the liver of *Tff1*^{KO} mice, *Tff3* expression is significantly down-regulated (Figure 2). *Tff3* is moderately expressed in biliary epithelial cells [88] and dramatic down-regulation of *Tff3* expression was observed in a murine model of type II diabetes [89]. *Tff3* down-regulation is also correlated with a fatty-liver phenotype [90]. Furthermore, *Tff3*^{KO} mice show altered liver lipid metabolism [91]. Thus, it would be interesting to check if a similar phenotype occurs in *Tff1*^{KO} mice.

4. Materials and Methods

4.1. Animals

Animal care and experimental procedures were conducted in compliance with the Directive 2010/63/EU of the European parliament and of the council of 22 September 2010 on the protection of animals used for scientific purposes, the German Animal Welfare Act, and the regulations on the welfare of animals used for experiments or for other scientific purposes in their currently valid versions. In the course of these studies, *Tff1*^{KO} mice and their corresponding wild-type littermates (mixed 129/Sv and C57BL/6 background) described previously [41,92] were investigated at the age of six weeks (Landesverwaltungsamt Sachsen-Anhalt; license number: 203.m-42502-2-1722 UniMD; 18 May 2022). Mice heterozygous for *Tff1* were originally obtained from Dr. M.-C. Rio and Dr. C. Tomasetto (IGBMC, Illkirch, France) [38]. Furthermore, for protein analysis, adult wild-type animals with a mixed 129/Sv and C57BL/6 background at the age of 16 weeks were used as described previously [6,93] (Animal Welfare Officer of the Medical Faculty of the Otto-von-Guericke University Magdeburg; license number: IMMC-TWZ-01; 1 January 2015).

4.2. RNA Extraction, PCR Analysis

Isolation of total intestinal, hepatic and pulmonary RNA, respectively, (TRIzol™ Reagent; ambion by life technologies, Carlsbad, CA, USA), of pancreatic RNA (RNA Mini Kit, Bioline, Heidelberg, Germany), as well as RT-PCR (reverse transcriptase: Takara Bio Europe, Saint Germain en Laye, France) were as previously described in detail [93–95].

The specific primer pairs used for RT-PCR have been published previously (*A4gnt*, MB2430/MB2431; *Actb*, MB2658/MB2659; *Fcgbp*, MB2448/MB2449; *Gast*, MB2450/MB2451; *Gkn1*, MB2450/MB2451; *Gkn2*, MB2456/MB2457; *Gkn3*, MB2656/MB2657; *Muc6*, MB2320/MB2321; *Pdia3*, MB2744/MB2745; *Pdx1*, MB2464/MB2474; *Tff1*, MD7/MD8; *Tff2*, MB2306/MB2307; *Tff3*, MB2470/MB2471) [22,41,93,95] or are listed in Table 1. All primer pairs used are intron-spanning.

Table 1. Oligonucleotides used for RT-PCR analysis and calculated size of the products.

Genes Accession No.	Primer No.	Primer Pairs	Nucleotide Positions	Annealing T Size (bp)
<i>Agr2</i> NM_011783.2	MB2190	GTCTGCAATCCTGCTTCTTGT	70–90	60 °C
	MB2191	GTCTTTAGCAGCTTGAGAGCTT	570–549	501
<i>Cdx1</i> NM_009880.4	MB2354	GGACGCCCTACGAATGGAT	489–507	60 °C
	MB2355	ACCAGATCTTTACCTGCCGC	704–685	216
<i>Cdx2</i> NM_007673.3	MB2352	AGCCAAGTGAAAACCAGGACA	799–819	60 °C
	MB2353	GATGCTGTTCGTGGGTAGGA	1320–1301	522
<i>Clca1</i> NM_017474.2	MB2176	CTTATCACCTGGACAACGCA	1589–1608	60 °C
	MB2177	TGGTCCCTGAGATCAACGAT	2436–2417	848
<i>Duox2</i> NM_001362755.1	MB2726	GCCTGTCCGAGTCTCGTTCAT	2934–2953	60 °C
	MB2727	CCGCAAGAAGGTGATGAGGT	3383–3364	450
<i>Fut2</i> NM_001271993.1	MB2468	CTCCCCCGGGATCCTTATCT	252–271	60 °C
	MB2469	GTGGTAATTCTGCCACGGG	699–681	448
<i>Lgr5</i> NM_010195.2	MB2492	GTCTCCTACATCGCCTCTGC	538–557	60 °C
	MB2493	AGAAGGGTTGCCTACGAACG	1133–1114	596
<i>Lpo</i> NM_080420.3	MB3005	GGCTGCCACGGGAGGTCAA	11–29	60 °C
	MB3006	TTATAGGGTGGTGTGGGGCA	906–887	896
<i>Mki67</i> NM_001081117.2	MB2458	AGAGCTAACTTGCCTGACTG	129–149	60 °C
	MB2459	TCTTGAGGCTCGCCTTGATG	618–599	490
<i>Muc2</i> NM_023566.4	MB2178	GGCTCTACAGACAAGCAGAC	1329–1348	60 °C
	MB2179	CATGAAGGTATGGTCAGGGC	2141–2122	813
<i>Nox1</i> NM_172203.2	MB2883	AAGTTTCTCTCCGAAGGACC	74–94	60 °C
	MB2884	CCCTCAAGAAGGACAGCAGA	387–368	314
<i>Pdia6</i> NM_027959.4	MB2991	TGGTCGGACGAGATCTGACA	806–825	60 °C
	MB2992	TGAGACGCTGAGGTTCACTG	1513–1494	708
<i>Qsox1</i> NM_001024945.1	MB2546	TATAGTGAGGCCACCCACA	1370–1389	60 °C
	MB2547	GTACATCTAGGGCAGTGGCTC	1895–1875	526
<i>Sod1</i> NM_011434.2	MB2837	CGGTGAACCAGTTGTGTTGTC	174–194	60 °C
	MB2838	GGTCTCCAACATGCCTCTCT	349–330	176
<i>Sod2</i> NM_013671.3	MB2839	CTGGACAAACCTGAGCCCTA	510–529	60 °C
	MB2840	GTTGTTCTTGCAATGGGTCC	728–708	219
<i>Sod3</i> NM_011435.3	MB2184	CTGCTGCTCGCTCACATAA	119–137	60 °C
	MB2185	CGCCTGGAGACATCTATGC	1077–1059	959
<i>Spdef</i> NM_013891.4	MB2200	AAGATATTGAGACGGCCTGC	790–809	60 °C
	MB2201	TGTCTATCTGGGACCTTGGG	1528–1509	739
<i>Zg16</i> NM_026918.3	MB2995	CCTCGGCCTCTGCTAATTCC	85–104	60 °C
	MB2996	CCTGGATCACAGATCCCCG	339–320	255

Semi-quantitative evaluation of the relative expression levels of the selected genes was performed using the GeneTools analysis software (Version 4.3.17.0, Syngene Bioimaging, Cambridge, UK), as previously described in detail [93]. Generally, the relative intensities were normalized against the relative intensities of the *Actb* transcripts (intestine 23 or 24, liver 24, lung 21, and pancreas 27 amplification cycles, respectively) and the highest value (mean) within each series was set to 1. If no robust signal was obtained (Figure 2: *Tff1*, *Tff2*/liver), an external signal was used as standard and set to 1. The statistical analysis using Student's t-test was performed with the Excel 2019 software package (Microsoft, Syracuse, NY, USA). Error bars represent \pm SEM. Significant differences between the mean values between wild-type and *Tff1*^{KO} mice are indicated by asterisks ($p \leq 0.05$: significant, *; $p \leq 0.01$: highly significant, **; $p \leq 0.001$: extremely highly significant, ***).

4.3. Extraction of Proteins, Protein Purification via SEC

Extraction and fractionation via SEC of total duodena from 4 animals were previously described in detail [22]. Furthermore, the caecum plus total colon from a single individual was collected and extracted with a 6.2-fold amount (*w/v*) of buffer (30 mM NaCl, 20 mM Tris-HCl pH 7.0 plus protease inhibitors) in a Precellys[®] 24 lyser/homogenizer, similarly to previous descriptions (aqueous extracts) [10,96]. A total of 5 mL of the extracts were fractionated via SEC with the ÄKTA[™] FPLC system (Amersham Biosciences, Freiburg, Germany) as described (fraction numbering: A1–A12, B1–B12, etc.), using a HiLoad 16/600 Superdex 75-prep-grade column (S75HL; 20 mM Tris-HCl pH 7.0, 30 mM NaCl plus protease inhibitors; flow rate: 1.0 mL/min; 2.0 mL fractions) [97].

4.4. SDS-PAGE, AgGE, and Western Blot Analysis

Denaturing SDS-PAGE under reducing and non-reducing conditions, respectively, native AgGE, and Western blot analysis were described previously [10,41,98,99]. When indicated, gels after non-reducing SDS-PAGE were subjected to post-in-gel reduction with 1% mercaptoethanol at 50 °C for 2 min, according to a previous report [97]. As a relative standard for non-denaturing AgGE, a DNA ladder was used as specified previously [15].

Murine *Tff1* and *Tff2* were detected with the affinity-purified polyclonal antisera anti-m*Tff1*-1 [94] and anti-TFF2 (PA5-75670; Invitrogen by Thermo Fisher Scientific Baltics UAB, Vilnius, Lithuania), respectively. For the detection of *Tff3*, the polyclonal antiserum, anti-r*Tff3*-1 [100], was used. *Fcgbp* was detected with a polyclonal antiserum against a fragment of rat *Fcgbp* kindly provided by Prof. Jürgen Seitz (Philipps University, Marburg, Germany) [101] and the mucin *Muc6* with the biotinylated lectin GSA-II from *G. simplicifolia*, as reported [97,102].

4.5. Identification of Proteins via Bottom-Up Proteomics

For protein identification, gel bands were excised and subjected to tryptic digestion, followed by liquid chromatography coupled to electrospray ionization and tandem mass spectrometry (LC-ESI-MS/MS). The data obtained were processed and analyzed with a search engine, as described in detail previously [15]. For N-terminal glutamine residues, cyclization to pyroglutamic acid (pyro-Glu) was also taken into account. This is a posttranslational modification, which is typical of some TFF peptides, but cyclization of free Gln and Glu can also occur in the electrospray ionization source [62].

5. Conclusions

In this study, different mucosal protection systems were systematically localized along the murine intestine (Figure 6). Remarkably, the evolutionary old *Muc6/A4gnt/Tff2* system is not restricted to the stomach and Brunner glands, but also protects the deep crypts, particularly of the proximal colon. In the latter, the expression of *Nox1* and of *Lpo* also culminate. A systematic investigation of the distinct parts of the colon is a future challenge. This might help to increase the understanding of the differences in the carcinogenesis in the distinct colonic regions. Furthermore, we characterized *Tff1-Fcgbp* heterodimers,

which are probably involved specifically in duodenal innate immune defense. Notably, *Tff1*-deficient animals show significantly up-regulated *Gkn1* and *Gkn2* expression in the proximal duodenum when compared with the wild-type. Furthermore, the expression of *Tff* genes is cross-regulated, particularly in the GI tract, leading to a down-regulation of *Tff2* and *Tff3* in *Tff1*^{KO} animals.

Author Contributions: Conceptualization, W.H.; mouse breeding management and collection of murine specimens, F.S., E.B.Z. and A.L.; investigations, F.S., E.B.Z. and A.L.; mass spectrometric proteomics, S.H. and H.S.; writing—original draft preparation, W.H.; writing—review and editing, F.S., E.B.Z., A.L., S.H. and H.S. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by the European Commission (ZS/2016/10/81609) and by grants from the Deutsche Forschungsgemeinschaft (DFG) (INST 337/15-1, INST 337/16-1, INST 152/837-1).

Institutional Review Board Statement: This study was approved by the Animal Welfare Officer of the Medical Faculty of the Otto-von-Guericke University Magdeburg (license number: IMMC-TWZ-01, 1 January 2015) and the Landesverwaltungsamt Sachsen-Anhalt (license number: 203.m-42502-2-1722 UniMD, 18 May 2022).

Acknowledgments: We thank Daniela Lorenz (Otto-von-Guericke University, Magdeburg) for her valuable secretarial assistance and help with the illustrations, Dr. Katharina Hauptenthal (Otto-von-Guericke University, Magdeburg) for mouse breeding management, and Dr. Jonathan A. Lindquist (Otto-von-Guericke University, Magdeburg) for his comments on the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

AGC	Antral gland cell
AgGE	Agarose gel electrophoresis
FCGBP	IgG Fc binding protein
GI	Gastrointestinal
GKN	Gastrokine
MNC	Mucous neck cell
SEC	Size exclusion chromatography
SDS-PAGE	Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
TFF	Trefoil factor family

References

- Clevers, H.; Batlle, E. SnapShot: The intestinal crypt. *Cell* **2013**, *152*, 1198–1198.e2. [\[CrossRef\]](#)
- Clevers, H. The intestinal crypt, a prototype stem cell compartment. *Cell* **2013**, *154*, 274–284. [\[CrossRef\]](#)
- Ley, R.E.; Hamady, M.; Lozupone, C.; Turnbaugh, P.J.; Ramey, R.R.; Bircher, J.S.; Schlegel, M.L.; Tucker, T.A.; Schrenzel, M.D.; Knight, R.; et al. Evolution of mammals and their gut microbes. *Science* **2008**, *320*, 1647–1651. [\[CrossRef\]](#)
- Garrett, W.S.; Gordon, J.I.; Glimcher, L.H. Homeostasis and inflammation in the intestine. *Cell* **2010**, *140*, 859–870. [\[CrossRef\]](#)
- Ermund, A.; Schütte, A.; Johansson, M.E.V.; Gustafsson, J.K.; Hansson, G.C. Studies of mucus in mouse stomach, small intestine, and colon. I. Gastrointestinal mucus layers have different properties depending on location as well as over the Peyer's patches. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2013**, *305*, G341–G347. [\[CrossRef\]](#) [\[PubMed\]](#)
- Vilchez-Vargas, R.; Salm, F.; Znalesniak, E.B.; Hauptenthal, K.; Schanze, D.; Zenker, M.; Link, A.; Hoffmann, W. Profiling of the bacterial microbiota along the murine alimentary tract. *Int. J. Mol. Sci.* **2022**, *23*, 1783. [\[CrossRef\]](#) [\[PubMed\]](#)
- Johansson, M.E.V.; Larsson, J.M.; Hansson, G.C. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. *Proc. Natl. Acad. Sci. USA* **2011**, *108* (Suppl. 1), 4659–4665. [\[CrossRef\]](#)
- Gustafsson, J.K.; Johansson, M.E.V. The role of goblet cells and mucus in intestinal homeostasis. *Nat. Rev. Gastroenterol. Hepatol.* **2022**, *19*, 785–803. [\[CrossRef\]](#)
- Holmén Larsson, J.M.; Thomsson, K.A.; Rodríguez-Piñeiro, A.M.; Karlsson, H.; Hansson, G.C. Studies of mucus in mouse stomach, small intestine, and colon. III. Gastrointestinal Muc5ac and Muc2 mucin O-glycan patterns reveal a regiospecific distribution. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2013**, *305*, G357–G363. [\[CrossRef\]](#)
- Albert, T.K.; Laubinger, W.; Müller, S.; Hanisch, F.-G.; Kalinski, T.; Meyer, F.; Hoffmann, W. Human intestinal TFF3 forms disulfide-linked heteromers with the mucus-associated FCGBP protein and is released by hydrogen sulfide. *J. Proteome Res.* **2010**, *9*, 3108–3117. [\[CrossRef\]](#) [\[PubMed\]](#)

11. Rodríguez-Piñeiro, A.M.; Bergström, J.H.; Ermund, A.; Gustafsson, J.K.; Schütte, A.; Johansson, M.E.V.; Hansson, G.C. Studies of mucus in mouse stomach, small intestine, and colon. II. Gastrointestinal mucus proteome reveals Muc2 and Muc5ac accompanied by a set of core proteins. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2013**, *305*, G348–G356. [[CrossRef](#)]
12. Lang, T.; Klasson, S.; Larsson, E.; Johansson, M.E.V.; Hansson, G.C.; Samuelsson, T. Searching the Evolutionary Origin of Epithelial Mucus Protein Components-Mucins and FCGBP. *Mol. Biol. Evol.* **2016**, *33*, 1921–1936. [[CrossRef](#)]
13. Nyström, E.E.L.; Birchenough, G.M.H.; van der Post, S.; Arike, L.; Gruber, A.D.; Hansson, G.C.; Johansson, M.E.V. Calcium-activated Chloride Channel Regulator 1 (CLCA1) Controls Mucus Expansion in Colon by Proteolytic Activity. *EBioMedicine* **2018**, *33*, 134–143. [[CrossRef](#)]
14. Hoffmann, W. Salivary Trefoil Factor Family (TFF) Peptides and Their Roles in Oral and Esophageal Protection: Therapeutic Potential. *Int. J. Mol. Sci.* **2021**, *22*, 12221. [[CrossRef](#)]
15. Weste, J.; Houben, T.; Harder, S.; Schlüter, H.; Lücke, E.; Schreiber, J.; Hoffmann, W. Different Molecular Forms of TFF3 in the Human Respiratory Tract: Heterodimerization with IgG Fc Binding Protein (FCGBP) and Proteolytic Cleavage in Bronchial Secretions. *Int. J. Mol. Sci.* **2022**, *23*, 15359. [[CrossRef](#)]
16. Park, S.W.; Zhen, G.; Verhaeghe, C.; Nakagami, Y.; Nguyenvu, L.T.; Barczak, A.J.; Killeen, N.; Erle, D.J. The protein disulfide isomerase AGR2 is essential for production of intestinal mucus. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 6950–6955. [[CrossRef](#)]
17. Bergström, J.H.; Berg, K.A.; Rodríguez-Piñeiro, A.M.; Stecher, B.; Johansson, M.E.V.; Hansson, G.C. AGR2, an endoplasmic reticulum protein, is secreted into the gastrointestinal mucus. *PLoS ONE* **2014**, *9*, e104186. [[CrossRef](#)] [[PubMed](#)]
18. Schumacher, U.; Duku, M.; Katoh, M.; Jörns, J.; Krause, W.J. Histochemical similarities of mucins produced by Brunner’s glands and pyloric glands: A comparative study. *Anat. Rec. A Discov. Mol. Cell. Evol. Biol.* **2004**, *278*, 540–550. [[CrossRef](#)] [[PubMed](#)]
19. Nakayama, J. Dual Roles of Gastric Gland Mucin-specific O-glycans in Prevention of Gastric Cancer. *Acta Histochem. Cytochem.* **2014**, *47*, 1–9. [[CrossRef](#)] [[PubMed](#)]
20. Oinuma, T.; Kawano, J.; Sukanuma, T. Glycoconjugate histochemistry of *Xenopus laevis* fundic gland with special reference to mucous neck cells during development. *Anat. Rec.* **1991**, *230*, 502–512. [[CrossRef](#)]
21. Hoffmann, W. TFF2, a MUC6-binding lectin stabilizing the gastric mucus barrier and more. *Int. J. Oncol.* **2015**, *47*, 806–816. [[CrossRef](#)] [[PubMed](#)]
22. Znalesniak, E.B.; Laskou, A.; Salm, F.; Hauptenthal, K.; Harder, S.; Schlüter, H.; Hoffmann, W. The Forms of the Lectin Tff2 Differ in the Murine Stomach and Pancreas: Indications for Different Molecular Functions. *Int. J. Mol. Sci.* **2023**, *24*, 7059. [[CrossRef](#)] [[PubMed](#)]
23. Ota, H.; Hayama, M.; Momose, M.; El-Zimaity, H.M.T.; Matsuda, K.; Sano, K.; Maruta, F.; Okumura, N.; Katsuyama, T. Co-localization of TFF2 with gland mucous cell mucin in gastric mucous cells and in extracellular mucous gel adherent to normal and damaged gastric mucosa. *Histochem. Cell Biol.* **2006**, *126*, 617–625. [[CrossRef](#)] [[PubMed](#)]
24. Belikov, A.V.; Schraven, B.; Simeoni, L. T cells and reactive oxygen species. *J. Biomed. Sci.* **2015**, *22*, 85. [[CrossRef](#)] [[PubMed](#)]
25. Aviello, G.; Knaus, U.G. NADPH oxidases and ROS signaling in the gastrointestinal tract. *Mucosal Immunol.* **2018**, *11*, 1011–1023. [[CrossRef](#)] [[PubMed](#)]
26. Bedard, K.; Krause, K.-H. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. *Physiol. Rev.* **2007**, *87*, 245–313. [[CrossRef](#)]
27. Allaoui, A.; Botteaux, A.; Dumont, J.E.; Hoste, C.; De Deken, X. Dual oxidases and hydrogen peroxide in a complex dialogue between host mucosae and bacteria. *Trends Mol. Med.* **2009**, *15*, 571–579. [[CrossRef](#)]
28. Sarr, D.; Tóth, E.; Gingerich, A.; Rada, B. Antimicrobial actions of dual oxidases and lactoperoxidase. *J. Microbiol.* **2018**, *56*, 373–386. [[CrossRef](#)]
29. Fattman, C.L.; Schaefer, L.M.; Oury, T.D. Extracellular superoxide dismutase in biology and medicine. *Free Radic. Biol. Med.* **2003**, *35*, 236–256. [[CrossRef](#)]
30. Menhenniott, T.R.; Kurklu, B.; Giraud, A.S. Gastrokines: Stomach-specific proteins with putative homeostatic and tumor suppressor roles. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2013**, *304*, G109–G121. [[CrossRef](#)]
31. Stappenbeck, T.S. Paneth cell development, differentiation, and function: New molecular cues. *Gastroenterology* **2009**, *137*, 30–33. [[CrossRef](#)]
32. Mowat, A.M.; Agace, W.W. Regional specialization within the intestinal immune system. *Nat. Rev. Immunol.* **2014**, *14*, 667–685. [[CrossRef](#)] [[PubMed](#)]
33. Braga Emidio, N.; Hoffmann, W.; Brierley, S.M.; Muttenthaler, M. Trefoil factor family: Unresolved questions and clinical perspectives. *Trends Biochem. Sci.* **2019**, *44*, 387–390. [[CrossRef](#)]
34. Hoffmann, W. Trefoil Factor Family (TFF) Peptides and Their Diverse Molecular Functions in Mucus Barrier Protection and More: Changing the Paradigm. *Int. J. Mol. Sci.* **2020**, *21*, 4535. [[CrossRef](#)] [[PubMed](#)]
35. Hoffmann, W. Trefoil Factor Family (TFF) Peptides. *Encyclopedia* **2021**, *1*, 974–987. [[CrossRef](#)]
36. Hauser, F.; Roeben, C.; Hoffmann, W. xP2, a new member of the P-domain peptide family of potential growth factors, is synthesized in *Xenopus laevis* skin. *J. Biol. Chem.* **1992**, *267*, 14451–14455. [[CrossRef](#)]
37. Stürmer, R.; Reising, J.; Hoffmann, W. The TFF peptides xP1 and xP4 appear in distinctive forms in the *Xenopus laevis* gastric mucosa: Indications for different protective functions. *Int. J. Mol. Sci.* **2019**, *20*, 6052. [[CrossRef](#)]
38. Lefebvre, O.; Chenard, M.-P.; Masson, R.; Linares, J.; Dierich, A.; LeMeur, M.; Wendling, C.; Tomasetto, C.; Chambon, P.; Rio, M.-C. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. *Science* **1996**, *274*, 259–262. [[CrossRef](#)]

39. Tomasetto, C.; Rio, M.-C. Pleiotropic effects of Trefoil Factor 1 deficiency. *Cell. Mol. Life Sci.* **2005**, *62*, 2916–2920. [[CrossRef](#)]
40. Hoffmann, W. Self-Renewal and Cancers of the Gastric Epithelium: An Update and the Role of the Lectin TFF1 as an Antral Tumor Suppressor. *Int. J. Mol. Sci.* **2022**, *23*, 5377. [[CrossRef](#)]
41. Znalesniak, E.B.; Salm, F.; Hoffmann, W. Molecular Alterations in the Stomach of *Tff1*-Deficient Mice: Early Steps in Antral Carcinogenesis. *Int. J. Mol. Sci.* **2020**, *21*, 644. [[CrossRef](#)] [[PubMed](#)]
42. Lefebvre, O.; Wolf, C.; Kédinger, M.; Chenard, M.P.; Tomasetto, C.; Chambon, P.; Rio, M.C. The mouse one P-domain (pS2) and two P-domain (mSP) genes exhibit distinct patterns of expression. *J. Cell Biol.* **1993**, *122*, 191–198. [[CrossRef](#)] [[PubMed](#)]
43. Playford, R.J.; Marchbank, T.; Goodlad, R.A.; Chinery, R.A.; Poulsom, R.; Hanby, A.M.; Wright, N.A. Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. *Proc. Natl. Acad. Sci. USA* **1996**, *93*, 2137–2142. [[CrossRef](#)] [[PubMed](#)]
44. Vandenbroucke, K.; Hans, W.; Van Huysse, J.; Neiryneck, S.; Demetter, P.; Remaut, E.; Rottiers, P.; Steidler, L. Active delivery of trefoil factors by genetically modified *Lactococcus lactis* prevents and heals acute colitis in mice. *Gastroenterology* **2004**, *127*, 502–513. [[CrossRef](#)]
45. Houben, T.; Harder, S.; Schlüter, H.; Kalbacher, H.; Hoffmann, W. Different forms of TFF3 in the human saliva: Heterodimerization with IgG Fc binding protein (FCGBP). *Int. J. Mol. Sci.* **2019**, *20*, 5000. [[CrossRef](#)]
46. Larsson, L.I.; Madsen, O.D.; Serup, P.; Jonsson, J.; Edlund, H. Pancreatic-duodenal homeobox 1 -role in gastric endocrine patterning. *Mech. Dev.* **1996**, *60*, 175–184. [[CrossRef](#)]
47. Hoffmann, W. Trefoil Factor Family (TFF) Peptides and their Different Roles in the Mucosal Innate Immune Defense and More: An Update. *Curr. Med. Chem.* **2021**, *28*, 7387–7399. [[CrossRef](#)]
48. Noah, T.K.; Kazanjian, A.; Whitsett, J.; Shroyer, N.F. SAM pointed domain ETS factor (SPDEF) regulates terminal differentiation and maturation of intestinal goblet cells. *Exp. Cell Res.* **2010**, *316*, 452–465. [[CrossRef](#)]
49. Carleton, A. The distribution of Brunner's glands in the duodenum of mammals. *Proc. Zool. Soc. Lond.* **1935**, *105*, 385–390. [[CrossRef](#)]
50. Judd, L.M.; Chaliner, H.V.; Walduck, A.; Pavlic, D.I.; Däbritz, J.; Dubeykovskaya, Z.; Wang, T.C.; Menheniott, T.R.; Giraud, A.S. TFF2 deficiency exacerbates weight loss and alters immune cell and cytokine profiles in DSS colitis, and this cannot be rescued by wild-type bone marrow. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2015**, *308*, G12–G24. [[CrossRef](#)]
51. Poulsen, S.S.; Thulesen, J.; Hartmann, B.; Kissow, H.L.; Nexø, E.; Thim, L. Injected TFF1 and TFF3 bind to TFF2-immunoreactive cells in the gastrointestinal tract in rats. *Regul. Pept.* **2003**, *115*, 91–99. [[CrossRef](#)] [[PubMed](#)]
52. Ota, H.; Nakayama, J.; Momose, M.; Kurihara, M.; Ishihara, K.; Hotta, K.; Katsuyama, T. New monoclonal antibodies against gastric gland mucous cell-type mucins: A comparative immunohistochemical study. *Histochem. Cell Biol.* **1998**, *110*, 113–119. [[CrossRef](#)] [[PubMed](#)]
53. Nakamura, N.; Ota, H.; Katsuyama, T.; Akamatsu, T.; Ishihara, K.; Kurihara, M.; Hotta, K. Histochemical reactivity of normal, metaplastic, and neoplastic tissues to alpha-linked *N*-acetylglucosamine residue-specific monoclonal antibody HIK1083. *J. Histochem. Cytochem.* **1998**, *46*, 793–801. [[CrossRef](#)]
54. Altmann, G.G. Morphological observations on mucus-secreting nongoblet cells in the deep crypts of the rat ascending colon. *Am. J. Anat.* **1983**, *167*, 95–117. [[CrossRef](#)] [[PubMed](#)]
55. Komiya, T.; Tanigawa, Y.; Hirohashi, S. Cloning of the gene *gob-4*, which is expressed in intestinal goblet cells in mice. *Biochim. Biophys. Acta* **1999**, *1444*, 434–438. [[CrossRef](#)]
56. Gupta, A.; Wodziak, D.; Tun, M.; Bouley, D.M.; Lowe, A.W. Loss of anterior gradient 2 (*Agr2*) expression results in hyperplasia and defective lineage maturation in the murine stomach. *J. Biol. Chem.* **2013**, *288*, 4321–4333. [[CrossRef](#)]
57. Bouchalova, P.; Sommerova, L.; Potesil, D.; Martisova, A.; Lapcik, P.; Koci, V.; Scherl, A.; Vonka, P.; Planas-Iglesias, J.; Chevet, E.; et al. Characterization of the AGR2 Interactome Uncovers New Players of Protein Disulfide Isomerase Network in Cancer Cells. *Mol. Cell. Proteom.* **2022**, *21*, 100188. [[CrossRef](#)]
58. Schumacher, M.A.; Liu, C.Y.; Katada, K.; Thai, M.H.; Hsieh, J.J.; Hansten, B.J.; Waddell, A.; Rosen, M.J.; Frey, M.R. Deep Crypt Secretory Cell Differentiation in the Colonic Epithelium Is Regulated by Sprouty2 and Interleukin 13. *Cell. Mol. Gastroenterol. Hepatol.* **2023**, *15*, 971–984. [[CrossRef](#)]
59. Barker, N.; van Es, J.H.; Kuipers, J.; Kujala, P.; van den Born, M.; Cozijnsen, M.; Haegebarth, A.; Korving, J.; Begthel, H.; Peters, P.J.; et al. Identification of stem cells in small intestine and colon by marker gene *Lgr5*. *Nature* **2007**, *449*, 1003–1007. [[CrossRef](#)]
60. Sasaki, N.; Sachs, N.; Wiebrands, K.; Ellenbroek, S.I.J.; Fumagalli, A.; Lyubimova, A.; Begthel, H.; van den Born, M.; van Es, J.H.; Karthaus, W.R.; et al. Reg4+ deep crypt secretory cells function as epithelial niche for *Lgr5*+ stem cells in colon. *Proc. Natl. Acad. Sci. USA* **2016**, *113*, E5399–E5407. [[CrossRef](#)]
61. Heuer, J.; Heuer, F.; Stürmer, R.; Harder, S.; Schlüter, H.; Braga Emidio, N.; Muttenthaler, M.; Jechorek, D.; Meyer, F.; Hoffmann, W. The Tumor Suppressor TFF1 Occurs in Different Forms and Interacts with Multiple Partners in the Human Gastric Mucus Barrier: Indications for Diverse Protective Functions. *Int. J. Mol. Sci.* **2020**, *21*, 2508. [[CrossRef](#)] [[PubMed](#)]
62. Purwaha, P.; Silva, L.P.; Hawke, D.H.; Weinstein, J.N.; Lorenzi, P.L. An artifact in LC-MS/MS measurement of glutamine and glutamic acid: In-source cyclization to pyroglutamic acid. *Anal. Chem.* **2014**, *86*, 5633–5637. [[CrossRef](#)] [[PubMed](#)]

63. Menheniott, T.R.; Peterson, A.J.; O'Connor, L.; Lee, K.S.; Kalantzis, A.; Kondova, I.; Bontrop, R.E.; Bell, K.M.; Giraud, A.S. A novel *gastrokine*, *Gkn3*, marks gastric atrophy and shows evidence of adaptive gene loss in humans. *Gastroenterology* **2010**, *138*, 1823–1835. [[CrossRef](#)] [[PubMed](#)]
64. Goto, Y.; Obata, T.; Kunisawa, J.; Sato, S.; Ivanov, I.I.; Lamichhane, A.; Takeyama, N.; Kamioka, M.; Sakamoto, M.; Matsuki, T.; et al. Innate lymphoid cells regulate intestinal epithelial cell glycosylation. *Science* **2014**, *345*, 1254009. [[CrossRef](#)] [[PubMed](#)]
65. Nanthakumar, N.N.; Meng, D.; Newburg, D.S. Fucosylated TLR4 mediates communication between mutualist fucotrophic microbiota and mammalian gut mucosa. *Front. Med.* **2023**, *10*, 1070734. [[CrossRef](#)] [[PubMed](#)]
66. Bry, L.; Falk, P.G.; Midtvedt, T.; Gordon, J.I. A model of host-microbial interactions in an open mammalian ecosystem. *Science* **1996**, *273*, 1380–1383. [[CrossRef](#)] [[PubMed](#)]
67. Hooper, L.V.; Xu, J.; Falk, P.G.; Midtvedt, T.; Gordon, J.I. A molecular sensor that allows a gut commensal to control its nutrient foundation in a competitive ecosystem. *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 9833–9838. [[CrossRef](#)]
68. Coyne, M.J.; Reinap, B.; Lee, M.M.; Comstock, L.E. Human symbionts use a host-like pathway for surface fucosylation. *Science* **2005**, *307*, 1778–1781. [[CrossRef](#)]
69. Comstock, L.E.; Kasper, D.L. Bacterial glycans: Key mediators of diverse host immune responses. *Cell* **2006**, *126*, 847–850. [[CrossRef](#)]
70. Nyström, E.E.L.; Martinez-Abad, B.; Arike, L.; Birchenough, G.M.H.; Nonnecke, E.B.; Castillo, P.A.; Svensson, F.; Bevins, C.L.; Hansson, G.C.; Johansson, M.E.V. An intercrypt subpopulation of goblet cells is essential for colonic mucus barrier function. *Science* **2021**, *372*, eabb1590. [[CrossRef](#)]
71. Wang, Y.; Huang, D.; Chen, K.-Y.; Cui, M.; Wang, W.; Huang, X.; Awadallah, A.; Li, Q.; Friedman, A.; Xin, W.W.; et al. Fucosylation Deficiency in Mice Leads to Colitis and Adenocarcinoma. *Gastroenterology* **2017**, *152*, 193–205. [[CrossRef](#)]
72. El Hassani, R.A.; Benfares, N.; Caillou, B.; Talbot, M.; Sabourin, J.-C.; Belotte, V.; Morand, S.; Gnidehou, S.; Agnandji, D.; Ohayon, R.; et al. Dual oxidase 2 is expressed all along the digestive tract. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2005**, *288*, G933–G942. [[CrossRef](#)] [[PubMed](#)]
73. Rigoni, A.; Poulosom, R.; Jeffery, R.; Mehta, S.; Lewis, A.; Yau, C.; Giannoulatou, E.; Feakins, R.; Lindsay, J.O.; Colombo, M.P.; et al. Separation of Dual Oxidase 2 and Lactoperoxidase Expression in Intestinal Crypts and Species Differences May Limit Hydrogen Peroxide Scavenging During Mucosal Healing in Mice and Humans. *Inflamm. Bowel Dis.* **2018**, *24*, 136–148. [[CrossRef](#)]
74. Geiszt, M.; Lekstrom, K.; Brenner, S.; Hewitt, S.M.; Dana, R.; Malech, H.L.; Leto, T.L. NAD(P)H oxidase 1, a product of differentiated colon epithelial cells, can partially replace glycoprotein 91^{phox} in the regulated production of superoxide by phagocytes. *J. Immunol.* **2003**, *171*, 299–306. [[CrossRef](#)]
75. Toback, F.G.; Walsh-Reitz, M.M.; Musch, M.W.; Chang, E.B.; Del Valle, J.; Ren, H.; Huang, E.; Martin, T.E. Peptide fragments of AMP-18, a novel secreted gastric antrum mucosal protein, are mitogenic and motogenic. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2003**, *285*, G344–G353. [[CrossRef](#)] [[PubMed](#)]
76. Kurt-Jones, E.A.; Cao, L.; Sandor, F.; Rogers, A.B.; Whary, M.T.; Nambiar, P.R.; Cerny, A.; Bowen, G.; Yan, J.; Takaishi, S.; et al. Trefoil factor 2 is expressed in murine gastric and immune cells and controls both gastrointestinal inflammation and systemic immune response. *Infect. Immun.* **2007**, *75*, 471–480. [[CrossRef](#)]
77. Bossenmeyer-Pouricé, C.; Kannan, R.; Ribieras, S.; Wendling, C.; Stoll, I.; Thim, L.; Tomasetto, C.; Rio, M.-C. The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. *J. Cell Biol.* **2002**, *157*, 761–770. [[CrossRef](#)]
78. Karam, S.M.; Tomasetto, C.; Rio, M.-C. Trefoil factor 1 is required for the commitment programme of mouse oxyntic epithelial progenitors. *Gut* **2004**, *53*, 1408–1415. [[CrossRef](#)] [[PubMed](#)]
79. Karam, S.M.; Tomasetto, C.; Rio, M.-C. Amplification and invasiveness of epithelial progenitors during gastric carcinogenesis in trefoil factor 1 knockout mice. *Cell Prolif.* **2008**, *41*, 923–935. [[CrossRef](#)]
80. Maurel, M.; Obacz, J.; Avril, T.; Ding, Y.P.; Papadodima, O.; Treton, X.; Daniel, F.; Pilalis, E.; Hörberg, J.; Hou, W.; et al. Control of anterior GRadiant 2 (AGR2) dimerization links endoplasmic reticulum proteostasis to inflammation. *EMBO Mol. Med.* **2019**, *11*, e10120. [[CrossRef](#)]
81. Delom, F.; Mohtar, M.A.; Hupp, T.; Fessart, D. The anterior gradient-2 interactome. *Am. J. Physiol. Cell Physiol.* **2020**, *318*, C40–C47. [[CrossRef](#)]
82. Torres, L.F.; Karam, S.M.; Wendling, C.; Chenard, M.P.; Kershenobich, D.; Tomasetto, C.; Rio, M.-C. Trefoil factor 1 (TFF1/pS2) deficiency activates the unfolded protein response. *Mol. Med.* **2002**, *8*, 273–282. [[CrossRef](#)]
83. Hoffmann, W.; Jagla, W. Cell type specific expression of secretory TFF peptides: Colocalization with mucins and synthesis in the brain. *Int. Rev. Cytol.* **2002**, *213*, 147–181.
84. Ribieras, S.; Lefebvre, O.; Tomasetto, C.; Rio, M.-C. Mouse Trefoil factor genes: Genomic organization, sequences and methylation analyses. *Gene* **2001**, *266*, 67–75. [[CrossRef](#)]
85. Hertel, S.C.; Chwieralski, C.E.; Hinz, M.; Rio, M.-C.; Tomasetto, C.; Hoffmann, W. Profiling trefoil factor family (TFF) expression in the mouse: Identification of an antisense TFF1-related transcript in the kidney and liver. *Peptides* **2004**, *25*, 755–762. [[CrossRef](#)]
86. Yamaguchi, J.; Mino-Kenudson, M.; Liss, A.S.; Chowdhury, S.; Wang, T.C.; Castillo, C.F.-D.; Lillemoe, K.D.; Warshaw, A.L.; Thayer, S.P. Loss of Trefoil Factor 2 From Pancreatic Duct Glands Promotes Formation of Intraductal Papillary Mucinous Neoplasms in Mice. *Gastroenterology* **2016**, *151*, 1232–1244. [[CrossRef](#)] [[PubMed](#)]

87. Hung, L.Y.; Oniskey, T.K.; Sen, D.; Krummel, M.F.; Vaughan, A.E.; Cohen, N.A.; Herbert, D.R. Trefoil Factor 2 Promotes Type 2 Immunity and Lung Repair through Intrinsic Roles in Hematopoietic and Nonhematopoietic Cells. *Am. J. Pathol.* **2018**, *188*, 1161–1170. [[CrossRef](#)] [[PubMed](#)]
88. Nozaki, I.; Lunz, J.G., 3rd; Specht, S.; Park, J.I.; Giraud, A.S.; Murase, N.; Demetris, A.J. Regulation and function of trefoil factor family 3 expression in the biliary tree. *Am. J. Pathol.* **2004**, *165*, 1907–1920. [[CrossRef](#)] [[PubMed](#)]
89. Brown, A.C.; Olver, W.I.; Donnelly, C.J.; May, M.E.; Naggert, J.K.; Shaffer, D.J.; Roopenian, D.C. Searching QTL by gene expression: Analysis of diabetes. *BMC Genet.* **2005**, *6*, 12. [[CrossRef](#)] [[PubMed](#)]
90. Guillén, N.; Navarro, M.-A.; Arnal, C.; Noone, E.; Arbonés-Mainar, J.M.; Acín, S.; Surra, J.C.; Muniesa, P.; Roche, H.M.; Osada, J. Microarray analysis of hepatic gene expression identifies new genes involved in steatotic liver. *Physiol. Genom.* **2009**, *37*, 187–198. [[CrossRef](#)]
91. Bujak, M.; Bujak, I.T.; Sobočanec, S.; Mihalj, M.; Novak, S.; Čosić, A.; Levak, M.T.; Kopačin, V.; Mihaljević, B.; Balog, T.; et al. Trefoil Factor 3 Deficiency Affects Liver Lipid Metabolism. *Cell. Physiol. Biochem.* **2018**, *47*, 827–841. [[CrossRef](#)] [[PubMed](#)]
92. Znalesniak, E.B.; Fu, T.; Guttek, K.; Händel, U.; Reinhold, D.; Hoffmann, W. Increased cerebral Tff1 expression in two murine models of neuroinflammation. *Cell. Physiol. Biochem.* **2016**, *39*, 2287–2296. [[CrossRef](#)]
93. Fu, T.; Znalesniak, E.B.; Kalinski, T.; Möhle, L.; Biswas, A.; Salm, F.; Dunay, I.R.; Hoffmann, W. TFF peptides play a role in the immune response following oral infection of mice with *Toxoplasma gondii*. *Eur. J. Microbiol. Immunol.* **2015**, *5*, 221–231. [[CrossRef](#)]
94. Fu, T.; Kalbacher, H.; Hoffmann, W. TFF1 is differentially expressed in stationary and migratory rat gastric epithelial cells (RGM-1) after in vitro wounding: Influence of TFF1 RNA interference on cell migration. *Cell. Physiol. Biochem.* **2013**, *32*, 997–1010. [[CrossRef](#)] [[PubMed](#)]
95. Znalesniak, E.B.; Fu, T.; Salm, F.; Händel, U.; Hoffmann, W. Transcriptional responses in the murine spleen after *Toxoplasma gondii* infection: Inflammasome and mucus-associated genes. *Int. J. Mol. Sci.* **2017**, *18*, 1245. [[CrossRef](#)] [[PubMed](#)]
96. Hanisch, F.-G.; Ragge, H.; Kalinski, T.; Meyer, F.; Kalbacher, H.; Hoffmann, W. Human gastric TFF2 peptide contains an N-linked fucosylated *N,N'*-diacetyllactosamine (LacdiNAc) oligosaccharide. *Glycobiology* **2013**, *23*, 2–11. [[CrossRef](#)] [[PubMed](#)]
97. Stürmer, R.; Müller, S.; Hanisch, F.-G.; Hoffmann, W. Porcine gastric TFF2 is a mucus constituent and differs from pancreatic TFF2. *Cell. Physiol. Biochem.* **2014**, *33*, 895–904. [[CrossRef](#)]
98. Jagla, W.; Wiede, A.; Kölle, S.; Hoffmann, W. Differential expression of the TFF-peptides xP1 and xP4 in the gastrointestinal tract of *Xenopus laevis*. *Cell Tiss. Res.* **1998**, *291*, 13–18. [[CrossRef](#)]
99. Kouznetsova, I.; Laubinger, W.; Kalbacher, H.; Kalinski, T.; Meyer, F.; Roessner, A.; Hoffmann, W. Biosynthesis of gastroskin-2 in the human gastric mucosa: Restricted spatial expression along the antral gland axis and differential interaction with TFF1, TFF2 and mucins. *Cell. Physiol. Biochem.* **2007**, *20*, 899–908. [[CrossRef](#)]
100. Probst, J.C.; Skutella, T.; Müller-Schmid, A.; Jirikowski, G.F.; Hoffmann, W. Molecular and cellular analysis of rP1.B in the rat hypothalamus: In situ hybridization and immunohistochemistry of a new P-domain neuropeptide. *Mol. Brain Res.* **1995**, *33*, 269–276. [[CrossRef](#)]
101. Wilhelm, B.; Keppler, C.; Henkeler, A.; Schilli-Westermann, M.; Linder, D.; Aumüller, G.; Seitz, J. Identification and Characterization of an IgG Binding Protein in the Secretion of the Rat Coagulating Gland. *Biol. Chem.* **2002**, *383*, 1959–1965. [[CrossRef](#)] [[PubMed](#)]
102. Ota, H.; Katsuyama, T. Alternating laminated array of two types of mucin in the human gastric surface mucous layer. *Histochem. J.* **1992**, *24*, 86–92. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.